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Summary Tumour-associated trypsin inhibitor (TATI) is a 6kD peptide isolated from the urine of a
patient with ovarian cancer. Increased urinary excretion of TATI has earlier been observed in patients with
gynaecological malignancies. The value of TATI in urine and serum as a marker for ovarian cancer was
studied in 102 patients. Preoperatively urine TATI was elevated in 55% (18/33) and serum TATI in 27%
(12/45) of the patients. In patients with mucinous tumours, elevated preoperative levels of TATI were
observed in 6 out of 10 patients, while CA 125 was elevated in 4 and CEA in one of the cases. When assay of
TATI was used to predict presence of disease before second-look surgery of 48 patients, the sensitivity and
specificity of serum TATI was 19% and 91%, and that of urine TATI 42% and 76%, respectively. Rising
TATI levels were observed in progressive disease, whereas regressive disease was not as often associated with
falling levels. Serum TATI was elevated in 45% (144/318) and urine TATI in 57% (73/171) of samples from
patients with clinical evidence of disease. The TATI assay was found to be of potential value in the
management of patients with mucinous ovarian cancer, but in patients with non-mucinous ovarian cancer it
did not provide information additional to that obtained from assay of ovarian cancer marker CA 125 alone.
Ovarian cancer is the most lethal of the gynaecological
malignancies. A majority of the cases are diagnosed at an
advanced stage and a reliable noninvasive method of
monitoring response to therapy has not been available.
A new marker for ovarian cancer, CA 125, appears to be
useful (Bast et al., 1983,1984). Elevated levels of CA 125
have been found in more than 80% of sera from patients
with ovarian cancer and the test is especially promising in
the follow-up of these patients (Bast et al., 1983; Kivinen et
al., 1986), Carcinoembryonic antigen (CEA) has been shown
to be useful only in a limited number of cases, mainly in
patients with mucinous ovarian cancer (van Nagell et al.,
1975; Rutanen et al., 1978).
Tumour-associated trypsin inhibitor, TATI, is a 6,000
dalton peptide isolated from the urine of a patient with
ovarian cancer. Determination of the N-terminal amino acid
sequence of TATI has revealed that it is closely related or
identical to the pancreatic secretory trypsin inhibitor (PSTI)
(Stenman et al., 1982; Huhtala et al., 1982). Elevated
concentrations of TATI have been found in the urine of
patients with gynaecological cancer, in amniotic fluid and in
some extracts from malignant tumours (Stenman et al.,
1982). In the first clinical study of TATI, increased urinary
excretion was found in 61% (11/18) of ovarian cancer
patients with evidence of disease (Huhtala et al., 1983).
In the present study, the usefulness of serum and urine
TATI levels in the diagnosis and monitoring of patients with
ovarian cancer was evaluated. The levels were compared
with the clinical stage and histopathologic type, clinical
course of the disease and findings at second-look surgery. In
addition we studied whether the combined use of TATI and
CA 125 would provide more data than the use of the CA 125
assay alone. In patients with mucinous ovarian tumours the
results were also compared with those obtained with CEA.
Materials and methods
Patients
The study comprised 582 serum and 239 urine samples from
102 patients with ovarian cancer. The age of the patients
varied from 19 to 82 years (median 59 years). The
histological diagnoses and the stages of the patients were
according to the FIGO classification (International
Correspondence: H. Halila
Received 25 June 1987; and in revised form 30 October 1987
Federation of Gynaecology and Obstetrics, 1965) (Table I).
Patients with two malignancies were excluded. Serum
samples were available from 45 patients and urine samples
from 33 patients before primary surgery, and serial samples
were collected at 1-6 month intervals on different occasions
in the post-treatment follow-up period of 2-48 months.
Serum and urine samples were stored at -20°C until
assayed.
The principles of therapy consisted of debulking surgery to
achieve the minimum tumour residuum and cytotoxic chemo-
therapy with a combination of cis-platinum, adriamycin
and cyclophosphamide every 4 weeks.
The response to treatment was evaluated according to the
recommendations of the American Cancer Society (Miller et
al., 1981). These included serial clinical observations of the
presence and size of the tumour, findings at second-look
laparotomy, laboratory and radiologic data. Disease
progression was defined as the appearance of- any new
lesions not previously identified, or an estimated increase of
25% or more in existing lesions. For disease regression, a
decrease in tumour size of 50% or more for at least four
weeks (partial response) or disappearance of all clinical signs
of malignancy (complete response) was required. The clinical
course of the disease was compared with the levels of serum
and urine TATI. Samples for this correlation were available
from 61 patients for serum TATI and for 45 patients for
urine TATI. The time interval between the first and last
sample compared with each other was 3-25 months (median
9 months) for serum TATI and 2-19 months (median 7
months) for urine TATI. A 100% increase or a 50%
decrease in TATI level was considered significant. Samples
Table I Histological diagnosis and stage of
the patients
Stage
Histology I II III IV
Serous 8 7 24 3 42
Mucinous 13 - 3 1 17
Endometrioid 2 - 3 2 7
Mesonephroid 1 1 1 1 4
Mixed 1 - - - I
Anaplastic - 3 16 6 25
Carcinosarcoma - - 2 - 2
Granulosa cell 2 - 2 - 4
27 11 51 13 102
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taken within one month post-operatively were excluded from
this comparison, because surgery may cause transient
elevation of TATI (Matsuda et al., 1985). Second-look
laparotomy was performed on 48 of the patients and the
levels of TATI and CA 125 before surgery were correlated
with surgical findings. Second-look surgery was usually
performed 6 to 12 months after the primary operation in
order to evaluate response to therapy. Multiple tissue
biopsies were taken for microscopic analysis. The findings
were divided into three groups: no evidence of disease,
microscopic evidence of disease and macroscopic evidence of
disease.
Radioimmunoassay
TATI was measured by radioimmunoassay as previously
described (Stenman et al., 1982; Huhtala et al., 1983). The
concentration of TATI in urine was correlated to the
concentration of creatinine in urine. Cut-off levels of
20ugl-1 in serum (Stenman et al., 1982) and 50pgg-1
creatinine in urine (Huhtala et al., 1983) were used.
The CA 125 assay was performed according to the
manufacturer's instructions (Centocor, Malvern, Pa., USA).
Values above 35Uml-1 were considered elevated on the
basis of earlier reports (Bast et al., 1982; Halila et al., 1986).
CEA was assayed by an immunoradiometric method using
reagents from Abbott Laboratories (North Chicago, Ill.,
USA). A cut-off level of 3pgI1 was used, which according
to the manufacturer includes 97% of healthy, non-smoking
subjects.
Results
Preoperative levels ofserum and urine TATI
Serum TATI was elevated in 26.7% (12/45) and urine TATI
in 54.5% (18/33) of the preoperative samples (Figure 1). In
the same patients, serum CA 125 was elevated in 82.2%
(37/45) and serum CEA in 16.1% (5/31). Two patients with
a normal preoperative CA 125 level had elevation of serum
TATI and another patient had elevation of TATI in urine.
These three patients all had stage I mucinous tumours. In
patients with mucinous tumours, elevated preoperative serum
TATI levels were observed in six cases, while CA 125 was
elevated in four and CEA in one (Table II). After successful
therapy, the elevated TATI and CA 125 levels fell to the
normal range in all stage I cases.
TATI levels and clinical course ofthe disease
There were 19 patients whose disease progressed, 35 patients
whose disease regressed and 7 who had a stable disease
during the follow-up period. In the group of patients with
progressive disease, there was a doubling of serum TATI
levels in 53% (10/19), and a doubling in urine TATI levels in
63% (10/16). In the group of patients with regressive disease,
there was a 50% decrease in serum TATI levels in 11%
(4/35), and in urine TATI levels in 28% (7/25). In most of
the rest of the patients, the change in TATI level reflected
the course of the disease, but the changes were smaller, and
in a few cases the change was opposite to the clinical course
(Figure 2). In the same patients, serum CA 125 levels
correlated positively with the course of the disease in 88% of
the patients whose tumour regressed during follow-up, and
in 87% of the patients who had progressive disease.
Levels of TATI before second-look laparatomy
Second-look surgery revealed evidence of disease in 26 of 48
patients. Eighteen of them had macroscopic and eight
microscopic evidence of disease. The diameter of the largest
tumour nodule discovered at operation was > cm in 12
patients and <1 cm in 6 patients. Twenty-two patients had
no evidence of disease. The levels of serum and urine TATI
before second-look surgery are presented in Table III.
Neither TATI nor CA 125 detected disease found at
second-look surgery with good sensitivity. The sensitivity of
serum TATI was 19%, of urine TATI 42%, and of CA 125
35%. Even in the group of patients with nodules larger than
cm, serum TATI was elevated in only 17% (2/12), urine
TATI in 50% (3/6), and CA 125 in 42% (5/12).
TATI levels and clinical status
The correlation between TATI level and presence or absence
of clinical disease was studied using different cut-off levels
(Table IV). In patients with evidence of disease, TATI in
urine was elevated more often (57.3%) than in serum (43.5%),
but the levels were also more often elevated in patients
without evidence of disease. The use of higher cut-off levels
increased specificity in NED, but decreased the specificity for
ED (Table IV).
In a patient with stage III mucinous cystadenocarcinoma,
highly elevated preoperative TATI and CA 125 levels became
normal after initial therapy, CA 125 more rapidly (Figure
3a). After 8 months a slight increase was observed if both
CA 125 and TATI, but only the latter became pathological.
During this period chemotherapy was given at monthly
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Figure 1 Preoperative levels of serum TATI and urine TATI in
patients with ovarian cancer divided into clinical stages according
to the FIGO classification. The upper limit of the reference range
for each assay is indicated by the horizontal lines.
Table II Preoperative serum levels of TATI, CA 125
and CEA in ten patients with mucinous ovarian
adenocarcinoma
Patients FIGO TATI CA 125 CEA
No. stage (ug1-1) (Uml-1) (Ugt1-1)
1 I 16 32 <3
2 I 13 20 <3
3 I 23 12 <3
4 I 12 33 <3
5 I 33 <7 <3
6 I 19 <7 <3
7 I 32 257 <3
8 III 52 158 57
9 III 851 8,300 <3
10 IV 23 159 <3
Elevated 6/10 4/10 1/10
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intervals. Second-look surgery was performed at 10 months
and no evidence of disease was detected. In a patient with
stage III serous cystadenocarcinoma (Figure 3b), serum and
urine TATI and CA 125 reflected disease course in a similar
fashion although serum TATI initially was normal.
There was a strong correlation (r=0.79) between TATI
levels in 158 samples of serum and urine obtained on the
same day.
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Figure 2 Levels of serum (a) and urine (b) TATI in samples
from patients during tumour regression, stable disease and
progression. The length of the follow-up time between con-
secutive samples is divided into three groups, <6 months, 6-12
months and > 12 months.
Table III Serum and urine TATI levels obtained before second-
look surgery in relation to surgical findings
Urine TATI
Serum TATI _50pgl1-
_20gl1- creatinine
ED macroscopic 3/18 4/8
_lcm 2/12 3/6
<1 cm 1/6 1/2
ED microscopic 3/8 1/4
NED 2/22 2/6
Sensitivity 19% 42%
Specificity 91% 67%
Predictive value of positive test 71% 71%
Predictive value of negative test 49% 36%
ED =evidence of disease; NED=no evidence of disease (on the
basis of surgical findings). The various groups of patients with
evidence of disease have been combined for the analyses of
sensitivity, specificity and predictive value.
Table 1V Distribution of TATI levels in 582 serum
and 239 urine samples from 102 patients with ovarian
cancer
Serum TATI Urine TATI
(pgl 1) (ugg-1 creatinine)
. 20 .30 .50 . 75
ED 45.3% 25.2% 57.3% 28.7%
NED 22.3% 4.9% 41.2% 14.7%
ED=evidence of disease; NED=no evidence of
disease. The assessment of disease is made on clinical
observations. The cut-off value for normal levels of
serum TATI is 20 ig 1, and of urine TATI 50Mugg
creatinine.
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Figure 3 Serum and urine TATI, CA 125 levels during follow-
up of a patient with stage III mucinous (a) and serous (b)
ovarian cancer (see text for details). S-TATI (0 O),
U-TATI (M *), CA 125 ( 0). Upper limits of the
reference range for each assay are indicated by the horizontal
lines.
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Discussion
The frequency ofelevated TATI levels in urine ofpatients with
ovarian cancer was in the same range as reported earlier (53%)
(Huhtala et al., 1983). In this respect TATI is more useful
than earlier used markers, e.g. CEA, alphafoetoprotein and
chorionic gonadotrophin. However, in non-mucinous
ovarian cancer, which represents most of the cases, CA 125 is
the best marker. TATI on the other hand appears to be the
better marker for mucinous ovarian cancer, for which
CA 125 is less efficient than for the non-mucinous types
(Kivinen et al., 1986; Brioschi et al., 1987). Therefore TATI
and CA 125 complement each other. The frequency of
preoperatively elevated TATI levels in mucinous cancer
(6/10) is notable because these patients mainly had stage I
disease (Table II), whereas non-mucinous cancers mainly
were of stage III (Table I).
The high frequency of elevated preoperative TATI levels
in mucinous cancer is expected, because very high levels of
TATI are found in mucinous ovarian cyst fluid, whereas
such levels are only occasionally found in serous tumours.
The latter tumours regularly contain high levels of CA 125,
the levels of which are lower in mucinous tumours (Halila et
al., 1987).
CEA has been considered to be more useful for mucinous
than for non-mucinous cancer (van Nagell et al., 1975;
Rutanen et al., 1978). We therefore also determined CEA
preoperatively in the patients with mucinous cancer, but this
marker was elevated in only one patient, who also had
elevated levels of TATI and CA 125.
Second-look surgery is routinely used to evaluate the
presence of residual disease after the initial treatment period.
Much effort could be saved if assay of serum or urine levels
of tumour markers could be used instead of surgery. In the
present study, presence of residual disease was predicted by
elevated levels of TATI in serum and urine in only 19% and
42%, respectively. However, CA 125 was not better in this
respect (sensitivity, 35%), as also noted earlier (Atack et al.,
1986). Thus normal levels of these markers do not eliminate
the need for second-look surgery.
The mechanism causing elevation of TATI in mucinous
tumours is most likely release of this marker from the
tumour. In other types of ovarian cancer other mechanisms
may contribute to the elevation, because high levels of TATI
are only occasionally found in the cyst fluid of non-
mucinous tumours (Halila et al., 1987). TATI may become
elevated not only in cancer but also in connection with
severe inflammatory (Huhtala et al., 1983), especially
hepatobiliary, disease (Haglund et al., 1986) and
postoperatively (Matsuda et al., 1985). This suggests that
TATI reacts to inflammation or tissue destruction, which
also occurs in connection with invasive cancer. Thus two
different mechanisms could cause elevation of TATI in
cancer, the one in mucinous ovarian cancer being similar to
that of most other tumour markers, whereas the other
mechanism could explain why TATI in some cases became
elevated with advanced disease, although preoperative levels
were normal. Non-specific reactions may also cause elevation
of other tumour markers, e.g. CA 125 in pelvic inflammatory
disease (Halila et al., 1986) and endometriosis (Barbieri et
al., 1986) and CEA in pancreatitis and hepatobiliary disease
(Haglund et al., 1986).
TATI in urine was elevated more often than TATI in
serum. Irrespective of the cause, it is apparent that assay of
TATI in urine is more useful than serum assay. However,
although TATI in urine generally seems to react more
sensitively to cancer than TATI in serum, the serum assay
appears to be sufficiently sensitive for mucinous ovarian
tumours. These results warrant further studies on the use of
TATI to monitor patients with mucinous ovarian cancer, for
which no good marker has been available.
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